These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 35877765)

  • 1. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.
    Gao W; Teng G; Wang C; Xu Y; Li Y; Cheng H
    Helicobacter; 2022 Oct; 27(5):e12918. PubMed ID: 35877765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies.
    Gao W; Xu Y; Liu J; Wang X; Dong X; Teng G; Liu B; Dong J; Ge C; Ye H; Zhang X; Cheng H
    Helicobacter; 2023 Apr; 28(2):e12947. PubMed ID: 36650673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
    Inokuchi K; Mori H; Matsuzaki J; Hirata K; Harada Y; Saito Y; Suzuki H; Kanai T; Masaoka T
    Helicobacter; 2022 Aug; 27(4):e12900. PubMed ID: 35644041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
    Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
    Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
    J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study.
    Peng X; Yao JY; Ma YQ; Li GH; Chen HW; Wan Y; Liang DS; Zhang M; Zhi M
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1210-1216. PubMed ID: 38309492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
    Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
    Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
    Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
    Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of vonoprazan-based rescue therapy for
    Yu J; Lv YM; Yang P; Jiang YZ; Qin XR; Wang XY
    World J Gastroenterol; 2023 May; 29(20):3133-3144. PubMed ID: 37346155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.
    Gunaratne AW; Hamblin H; Clancy A; Magat AJMC; Dawson MVM; Tu J; Borody TJ
    Helicobacter; 2021 Oct; 26(5):e12830. PubMed ID: 34247436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vonoprazan: A Review in Helicobacter pylori Infection.
    Shirley M
    Drugs; 2024 Mar; 84(3):319-327. PubMed ID: 38388872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
    Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T
    Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
    Liu L; Shi H; Shi Y; Wang A; Guo N; Li F; Nahata MC
    Helicobacter; 2024; 29(3):e13094. PubMed ID: 38790090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
    Han S; Deng Z; Cheung K; Lyu T; Chan P; Li Y; Ni L; Luo X; Li K
    BMC Gastroenterol; 2023 Jul; 23(1):231. PubMed ID: 37420205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vonoprazan-amoxicillin dual regimen with
    Dirjayanto VJ; Audrey J; Simadibrata DM
    World J Gastroenterol; 2024 Mar; 30(10):1280-1286. PubMed ID: 38596495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
    Han YY; Zhou L; Hu YL; Ding XW; Long H; Liu F; Xu M; Zhang ZY; Li SL; Wang QY; Su CX; Chen Y; Chen J; Lin Y; Li PY
    J Gastroenterol; 2023 Dec; 58(12):1167-1177. PubMed ID: 37777987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
    Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
    J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.